Dr. Reddy's Secures Exclusive India Rights to Takeda's Qdenga Dengue Vaccine
RDY is trading near its 52-week low of $11.36 (8.7% above the low).
Summary
Dr. Reddy's will exclusively distribute and market Takeda's Qdenga® dengue vaccine in India's private market, with no upfront payments and launch expected in H1 2027.
Key Events · M&A and Partnerships · RDY
-
Exclusive Qdenga Distribution Deal
Dr. Reddy's signed an exclusive distribution and marketing agreement with Takeda for Qdenga® in India's private market for pediatric and adult vaccination.
-
No Upfront Consideration
The agreement involves no upfront consideration or milestone payments; other commercial terms are confidential.
-
Launch Timeline
Subject to completion of applicable processes with local authorities, Qdenga® is anticipated to become available in India in the first half of 2027.
-
First Approved Dengue Vaccine
Qdenga® received CDSCO marketing authorization in July 2026 for individuals aged 4-60 years, making it India's first approved dengue vaccine.
Analysis · RDY · Life Sciences
Dr. Reddy's has entered into an exclusive distribution and marketing agreement with Takeda for Qdenga®, India's first CDSCO-approved dengue vaccine, covering the private market. The deal requires no upfront consideration or milestone payments, with the vaccine expected to launch in the first half of 2027. This partnership strengthens Dr. Reddy's vaccines business in India and positions it to capture a significant share of the private dengue vaccination market, which is growing rapidly as reported dengue cases have increased 11-fold over the past two decades.
How filings like this one have moved
In the 30 days to Sep 18, 2026, 29.2% of the 1713 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.36%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, RDY was trading at $12.35 on NYSE in the Life Sciences sector, with a market capitalization of approximately $10.2B. The 52-week trading range was $11.36 to $15.67. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.